As of March, 11 Avid Bioservices, Inc. (CDMO) EPS Estimated At $-0.07

Avid Bioservices, Inc. (NASDAQ:CDMO)’s earnings release is awaited by WallStreet on March, 11, as reported by Faxor. Analysts expect change of 69.57 % or $0.16 from previous year’s $-0.23 EPS compared to current’s $-0.07 EPS. Analysts at Wall Street see Avid Bioservices, Inc.’s 16.67 % negative EPS growth compared to $-0.06 EPS for last quarter. Ticker’s shares touched $3.85 during the last trading session after 8.15% change.Currently Avid Bioservices, Inc. is downtrending after 2.07% change in last February 12, 2018. CDMO has 168,823 shares volume. CDMO underperformed the S&P500 by 2.07%.

Avid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture.The company has $215.86 million market cap. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.Last it reported negative earnings. The firm produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support.

For more Avid Bioservices, Inc. (NASDAQ:CDMO) news announced briefly go to:,,, or The titles are as follows: “iBio to Present at Brazilian Ministry of Health’s Plant-Made Pharmaceutical Meeting – GlobeNewswire” announced on December 03, 2018, “Avid Bioservices to Present at Upcoming Investor Conferences – GlobeNewswire” on August 29, 2018, “Is Avid’s Backlog About To Explode? – Seeking Alpha” with a publish date: June 11, 2018, “Avid Bioservices to Participate at INTERPHEX 2018 Nasdaq:CDMO – GlobeNewswire” and the last “Avid Bioservices to Exhibit at the 17th Annual Contracting & Outsourcing Conference – GlobeNewswire” with publication date: September 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.